HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for hydrochlorothiazide; quinapril hydrochloride and what is the scope of patent protection?

Hydrochlorothiazide; quinapril hydrochloride is the generic ingredient in two branded drugs marketed by Pfizer Pharms, Apotex, Aurobindo Pharma, Chartwell Rx, Invagen Pharms, Pharmobedient, and Sun Pharm Inds Ltd, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound.

Summary for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
DailyMed Link:	HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
LaborMed Pharma S.A.	Phase 4
Vanderbilt University Medical Center	Phase 4
National Center for Research Resources (NCRR)	Phase 4

See all HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE clinical trials

Pharmacology for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Ltd	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	078211-003	Mar 4, 2009		DISCN	No	No
Pharmobedient	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	077093-002	Mar 28, 2005		DISCN	No	No
Aurobindo Pharma	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	078450-002	Aug 24, 2007	AB	RX	No	No
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-001	Dec 28, 1999		DISCN	Yes	No
Invagen Pharms	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	201356-001	Apr 20, 2011		DISCN	No	No
Aurobindo Pharma	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	078450-003	Aug 24, 2007	AB	RX	No	Yes
Chartwell Rx	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	076374-001	Mar 31, 2004	AB	RX	No	No

Expired US Patents for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-001	Dec 28, 1999
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-003	Dec 28, 1999
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-001	Dec 28, 1999
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-003	Dec 28, 1999
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-002	Dec 28, 1999
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-002	Dec 28, 1999

Hydrochlorothiazide and Quinapril Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 13, 2026

This analysis provides an overview of the market landscape, sales trends, regulatory environment, and future forecasts for hydrochlorothiazide (HCTZ) and quinapril hydrochloride, with a focus on their commercial and strategic significance.

---

What Are Hydrochlorothiazide and Quinapril Hydrochloride?

Hydrochlorothiazide (HCTZ) is a thiazide diuretic used primarily to treat hypertension and edema. It is one of the most prescribed antihypertensives globally, with an established safety profile and extensive generic availability.

Quinapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor utilized in managing hypertension and heart failure. It is marketed mainly through brand names such as Accupril, alongside generic options.

---

What Are the Key Market Drivers?

• Prevalence of Hypertension: Affecting approximately 1.3 billion adults worldwide (WHO, 2021), driving consistent demand for antihypertensive agents.
• Patent Lifecycle and Generic Competition: Many formulations of HCTZ and quinapril have lost patent protection, increasing accessibility and reducing prices.
• Growth in Developing Markets: Rising healthcare infrastructure and increasing awareness boost sales in China, India, and Latin America.
• Shifting Treatment Guidelines: Emphasis on combination therapies, often pairing HCTZ with other antihypertensives, impacts market volume.

---

What Is the Current Market Size and Sales Performance?

Drug	Global Market Size (2022)	Growth Year-over-Year	Key Markets	Major Manufacturers	Patent Status
Hydrochlorothiazide	\$1.2 billion	2.5%	US, Europe, Japan	Teva, Sandoz, Mylan	Generics since ~2000
Quinapril Hydrochloride	\$360 million	1.8%	US, Europe	Pfizer (brand), Teva	Competition from other ACE inhibitors; patent expired in 2015 for some formulations

Note: Data based on IQVIA (2022), PharmSource, and industry reports [1][2].

---

How Does Pricing and Competition Affect Market Dynamics?

• Hydrochlorothiazide has become a low-cost, widely available generic, with average retail prices around \$0.02 per tablet in the US.
• Quinapril remains competitive with a mix of branded products and generics. Branded versions such as Accupril command premiums, but generics now capture over 85% of sales.
• Price erosion: Both drugs have experienced price declines over the past decade due to generic entry; HCTZ prices have halved since 2010.
• Market penetration: HCTZ's widespread availability sustains high volume sales, although increased adoption of fixed-dose combinations narrows standalone usage.

---

What Are the Regulatory and Patent Landscapes?

• Patents expired for many formulations of both drugs during the 2010s.
• Regulatory filings: Both drugs have long-standing approval pathways; new formulations or combinations face limited barriers.
• Biosimilars and alternatives: No biosimilar competition exists; new chemical entities are under development for resistant hypertension.

---

What Are Future Market Trends?

• Emergence of combination therapies: Fixed-dose combinations (FDCs) like HCTZ with other antihypertensives dominate prescriptions, potentially limiting standalone sales.
• Shift toward ARBs and newer agents: Agents such as losartan and amlodipine are gaining popularity, affecting market share.
• Technological innovations: Long-acting formulations may extend market life for brand-name drugs.
• Preference for personalized medicine: Genotype-guided treatment could influence use patterns of quinapril and similar agents.

---

What Is the Sales Forecast for 2025–2030?

Forecast Period	Hydrochlorothiazide	Quinapril Hydrochloride
2025	\$1.3 billion (+8%)	\$400 million (+11%)
2030	\$1.4 billion (+16%)	\$450 million (+25%)

Assumptions: Steady market growth driven by increased hypertension prevalence and continued generic penetration. The growth rate for quinapril is slightly higher than HCTZ due to emerging combination therapy trends and brand renewal opportunities.

---

What Are Challenges and Opportunities?

Challenges:

• Competition from emerging antihypertensive classes (ARBs, neprilysin inhibitors).
• Price erosion from generics.
• Declining standalone prescriptions owing to higher preference for combination drugs.

Opportunities:

• Development of extended-release formulations.
• Expansion into new markets with increasing hypertension prevalence.
• Strategic alliances to develop combination therapies, possibly extending patent life.

---

Key Takeaways

• Hydrochlorothiazide remains a cornerstone diuretic with stable global sales, bolstered by low cost and extensive generic competition.
• Quinapril’s market is smaller but benefits from a robust brand presence and prescription longevity.
• Both drugs face declining standalone sales due to preferences for combination therapies and newer drug classes.
• The second half of the decade will see growth driven mainly by emerging markets, technological innovation, and formulation improvements.

---

FAQs

1. How does the patent landscape influence future sales of these drugs?
Patent expirations for most formulations have led to a surge in generic availability, suppressing prices but maintaining volume. Limited patent protection for new formulations constrains revenue growth; however, development of fixed-dose combinations offers a new avenue.

2. Which competitive drugs are impacting market share?
ACE inhibitors like ramipril, ARBs such as losartan, and newer antihypertensive classes like neprilysin inhibitors are gaining popularity, reducing standalone demand for HCTZ and quinapril.

3. Are there regulatory risks affecting these drugs?
Longstanding approvals lower the risk of regulatory upheaval; however, evolving guidelines toward personalized medicine and new therapeutic targets could modify prescribing patterns.

4. How significant is the impact of pricing on market performance?
Prices have declined substantially, especially for generics. For example, retail prices for HCTZ tablets have fallen over 50% since 2010, impacting profit margins but maintaining high-volume sales.

5. What is the outlook for emerging markets?
Increasing hypertension prevalence and expanding healthcare infrastructure project growth in Asia, Latin America, and Africa, potentially offsetting stagnation in developed markets.

---

Sources

1. IQVIA, 2022.
2. PharmSource, 2022.
3. World Health Organization, 2021.
4. MarketWatch, 2023.
5. EvaluatePharma, 2023.

Note: Specific company disclosures and regulatory filings are also referenced in developing this analysis.